P + LYMED

POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020, Phone: 011-26321889, Fax: 011-26321894
Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2016

							Rs. In lacs)	
		Quarter ended			Half Year Ended		Year ended	
	Particulars	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016	
- [(Unaudited)			(Unaudited)		(Audited)	
1	Income from operations						77 770 77	
a	Net sales / income from operations	10,474.51	10,249.33	10,091.38	20,723.84	19,672.83	39,539.68	
	(inclusive of excise duty) - refer note no. 3							
ь	Other operating income	188.17	166.11	96.56	354.28	175.63	475.76	
	Total income from operations (gross)	10,662.68	10,415.44	10,187.94	21,078.12	19,848.46	40,015.44	
2	Expenses							
a	Cost of materials consumed	3,229.89	3,565.05	3,479.83	6,794.94	6,922.07	13,177.2	
_	Purchases of stock-in-trade	136.05	171.90	168.06	307.95	311.83	676.1	
-	Changes in inventories of finished goods, work-in-progress and stock- in-trade	(165.45)	(253.93)	24.46	(419.38)	90.60	200.2	
_	Excise Duty on sales	153.49	146.66	141.57	300.15	271.90	567.6	
	Employee benefits expense	2,015.52	1,989.14	1,715.94	4,004.66	3,287.00	6,899.2	
f	Depreciation and amortisation expense	552.07	533.09	494.81	1,085.16	1,012.50	2,018.7	
a	Other expenses	2,996.52	2,482.59	2,589.46	5,479.11	5,095.15	10,048.7	
-	Total expenses	8,918.09	8,634.50	8,614.13	17,552.59	16,991.05	33,588.0	
3	Profit from operations before other income, finance costs and exceptional items (1-2)	1,744.59	1,780.94	1,573.81	3,525.53	2,857.41	6,427.30	
-	Other income	219.61	203.20	299.08	422.81	470.25	838.5	
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	1,964.20	1,984.14	1,872.89	3,948.34	3,327.66	7,265.8	
6	Finance costs	160.13	187.63	153.26	347.76	352.75	778.2	
-	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,804.07	1,796.51	1,719.63	3,600.58	2,974.91	6,487.6	
Q	Exceptional items	-	3	128	9.1	2	-	
	Profit from ordinary activities before tax (7 + 8)	1,804.07	1,796.51	1,719.63	3,600.58	2,974.91	6,487.6	
_	Tax expense	561.47	530.13	458.42	1,091.60	738.32	1,756.8	
	Net Profit from ordinary activities after tax (9 - 10)	1,242.60	1,266.38	1,261.21	2,508.98	2,236.59	4,730.7	
_	Extraordinary items	3 2	-	:=1	1.5		12.	
	Net Profit for the period (11 + 12)	1,242.60	1,266.38	1,261.21	2,508.98	2,236.59	4,730.7	
	Paid-up equity share capital (Face Value of Rs. 5 each)	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.6	
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	9					20,177.8	
16	Earnings per share (before extraordinary items) (Quarterly not annualised amd yearly annualised) : Basic (Rs.) Diluted (Rs.)	2.82 2.82	2.87 2.87	2.86 2.86	5.69 5.69	5.07 5.07	10. 10.	

	Statement of Assets and Liabilities	As	As at			
	Particulars	30.09.2016	31.03.2016			
		(Unaudited)	(Audited)			
A	EQUITY AND LIABILITIES					
1	Shareholders' funds					
	(a) Share capital	2,205.67	2,205.67			
	(b) Reserves and surplus	22,166.59	20,177.89			
	Sub-total - Shareholders' funds	24,372.26	22,383.56			
2	Minority interest		Ĭ.			
3	Non-current liabilities					
_	(a) Long-term borrowings	3,355.83	3,106.28			
	(b) Deferred tax liabilities (net)	1,278.97	1,183.37			
	(c) Other long-term liabilities	483.02	357.99			
	(d) Long-term provisions	286.56	256.51			
	Sub-total - Non-current liabilities	5,404.38	4,904.15			
	Current liabilities					
	(a) Short-term borrowings	2,859.03	3,039.38			
	(b) Trade payables	2,925.38	2,957.53			
	(c) Other current liabilities	4,415.45	3,797.33			
	(d) Short-term provisions	883.70	503.08			
	Sub-total - Current liabilities	11,083.56	10,297.32			
	TOTAL - EQUITY AND LIABILITIES	40,860.20	37,585.03			
В	ASSETS					
- 8	Non-current assets					

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th November, 2016 and have also been limited reviewed by Statutory Auditor of the Company.
- The Board of Directors of the company have declared interim
 Dividend of Rs. 1 per equity share having face value of Rs. 5 each
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICA1.
- Revenue from operations for the quarter ended 30th September 2016 and for all comparable periods / year ended 31st March 2016 is grossed up with the amount of excise duty on sales and the same is being shown as part of expenditure in accordance with SEBI clarification dated 20th September 2016.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

NEW DELHI

TOTAL - ASSETS	40,860.20	37,585.03	Date : 09.11.2016	Managing Director
Sub-total - Current assets	18,476.82	16,299.82	Place : New Delni	Himanshu Baid
(e) Other current assets	826.18	781.57	Place : New Delhi	humacht!
(d) Short-term loans and advances	1,379.71	1,283.06	/	By order of the Board
(c) Cash and bank balances	2,348.59	2,147.87		
(b) Trade receivables	8,996.85	8,029.07		
(a) Inventories	4,925.49	4,058.25		
Current assets				
Sub-total - Non-current assets	22,383.38	21,285.21		
(d) Other non-current assets	283.40	336.47		
(c) Long-term loans and advances	1,572.30	1,290.91		
(b) Non-current investments	561.06	561.06		
(a) Fixed assets	19,966.62	19,096.77		





DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors

Poly Medicure Limited 232B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi – 110 020.

Dear Sirs,

- 1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended September 30, 2016. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015'), which has been initiated by us for identification purposes. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the "Listing Regulations, 2015', including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates

Chartered Accountants

Reg. No.000561N

(M. S. Agarwal)

Partner

M. No. 86580

Place of Signature: New Delhi Date: 09/11/2016.